Stockreport

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Just Slashed This Year's Estimates [Yahoo! Finance]

Entrada Therapeutics, Inc.  (TRDA) 
PDF Revenue and earnings per share (EPS) forecasts were both revised downwards, with the analysts seeing grey clouds on the horizon. Shares are up 5.5% to US$12.41 in the pa [Read more]